Next Article in Journal
Antifungal Properties of Chenopodium ambrosioides Essential Oil Against Candida Species
Previous Article in Journal
Antidepressants and Suicide Risk: A Comprehensive Overview
Pharmaceuticals 2010, 3(9), 2884-2899; doi:10.3390/ph3092884
Review

Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?

*  and
Icagen, Inc., 4222 Emperor Blvd, Durham, NC 27703, USA
* Author to whom correspondence should be addressed.
Received: 19 August 2010 / Revised: 25 August 2010 / Accepted: 1 September 2010 / Published: 1 September 2010
View Full-Text   |   Download PDF [194 KB, uploaded 1 September 2010]   |   Browse Figures

Abstract

Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2nd and 3rd generation AEDs as well as compounds in development with novel mechanisms of action.
Keywords: epilepsy; antiepileptic; AED; seizure; anticonvulsant epilepsy; antiepileptic; AED; seizure; anticonvulsant
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Gerlach, A.C.; Krajewski, J.L. Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Pharmaceuticals 2010, 3, 2884-2899.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert